ID
int64 6
67
| author
stringclasses 23
values | year
int64 2.01k
2.02k
| cancerType
stringclasses 13
values | cellLine
stringclasses 27
values | time
int64 8
144
| coumarin
stringclasses 2
values | coumarinDose
float64 0.1
335
| viability
float64 3.66
109
| viabilitySD
float64 0.5
24.6
| viabilityN
int64 2
6
| control
float64 77.3
111
| controlSD
float64 0.86
12.5
| controlN
int64 2
6
|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 24 | Auraptene | 16.7 | 93.61 | 6.39 | 3 | 85.81 | 2.13 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 24 | Auraptene | 33.4 | 85.81 | 2.13 | 3 | 85.81 | 2.13 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 24 | Auraptene | 66.8 | 78.95 | 8.04 | 3 | 85.81 | 2.13 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 24 | Auraptene | 133.6 | 52 | 11.35 | 3 | 85.81 | 2.13 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 48 | Auraptene | 16.7 | 92.67 | 4.49 | 3 | 96.69 | 3.31 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 48 | Auraptene | 33.4 | 79.9 | 5.2 | 3 | 96.69 | 3.31 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 48 | Auraptene | 66.8 | 53.19 | 4.49 | 3 | 96.69 | 3.31 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 48 | Auraptene | 133.6 | 37.58 | 5.91 | 3 | 96.69 | 3.31 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 72 | Auraptene | 16.7 | 97.87 | 1.42 | 3 | 92.9 | 2.84 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 72 | Auraptene | 33.4 | 91.48 | 6.62 | 3 | 92.9 | 2.84 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 72 | Auraptene | 66.8 | 60.04 | 14.19 | 3 | 92.9 | 2.84 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 72 | Auraptene | 133.6 | 44.2 | 5.44 | 3 | 92.9 | 2.84 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 96 | Auraptene | 16.7 | 84.86 | 5.21 | 3 | 90.7 | 2.12 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 96 | Auraptene | 33.4 | 69.97 | 4.26 | 3 | 90.7 | 2.12 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 96 | Auraptene | 66.8 | 65.01 | 6.43 | 3 | 90.7 | 2.12 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 96 | Auraptene | 133.6 | 43.26 | 3.54 | 3 | 90.7 | 2.12 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 120 | Auraptene | 16.7 | 74.94 | 11.34 | 3 | 92.9 | 7.1 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 120 | Auraptene | 33.4 | 72.1 | 10.16 | 3 | 92.9 | 7.1 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 120 | Auraptene | 66.8 | 69.97 | 6.43 | 3 | 92.9 | 7.1 | 3 |
6 | Movaffagh et al. | 2,021 | Gastric | MKN-45 | 120 | Auraptene | 133.6 | 41.13 | 5.67 | 3 | 92.9 | 7.1 | 3 |
8 | Jamialahmadi et al. | 2,018 | Ovarian | A2780 | 24 | Auraptene | 31.49 | 50 | 5.83 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Cervical | Hela | 24 | Auraptene | 47.93 | 50 | 5.83 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Ovarian | A2780 | 24 | Auraptene | 3.13 | 88.38 | 6.36 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Ovarian | A2780 | 24 | Auraptene | 6.25 | 82.32 | 2.38 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Ovarian | A2780 | 24 | Auraptene | 12.5 | 71.21 | 5.57 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Ovarian | A2780 | 24 | Auraptene | 25 | 55.34 | 6.1 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Ovarian | A2780 | 24 | Auraptene | 50 | 41.59 | 3.44 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Ovarian | A2780 | 24 | Auraptene | 100 | 22.53 | 0.79 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Cervical | Hela | 24 | Auraptene | 3.13 | 88.35 | 11.65 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Cervical | Hela | 24 | Auraptene | 6.25 | 85.44 | 7.41 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Cervical | Hela | 24 | Auraptene | 12.5 | 72.25 | 19.84 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Cervical | Hela | 24 | Auraptene | 25 | 69.04 | 5.03 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Cervical | Hela | 24 | Auraptene | 50 | 64.28 | 9.26 | 3 | 100 | 3.36 | 3 |
8 | Jamialahmadi et al. | 2,018 | Cervical | Hela | 24 | Auraptene | 100 | 18.78 | 3.45 | 3 | 100 | 3.36 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 48 | Auraptene | 5 | 93.33 | 8.23 | 3 | 95.68 | 3.13 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 48 | Auraptene | 10 | 94.5 | 4.7 | 3 | 95.68 | 3.13 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 48 | Auraptene | 20 | 92.15 | 6.66 | 3 | 95.68 | 3.13 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 48 | Auraptene | 40 | 85.88 | 4.7 | 3 | 95.68 | 3.13 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 48 | Auraptene | 80 | 65.88 | 6.27 | 3 | 95.68 | 3.13 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 72 | Auraptene | 5 | 93.72 | 3.92 | 3 | 88.23 | 8.62 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 72 | Auraptene | 10 | 85.88 | 7.84 | 3 | 88.23 | 8.62 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 72 | Auraptene | 20 | 83.13 | 7.05 | 3 | 88.23 | 8.62 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 72 | Auraptene | 40 | 76.86 | 10.19 | 3 | 88.23 | 8.62 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 72 | Auraptene | 80 | 64.31 | 8.23 | 3 | 88.23 | 8.62 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 96 | Auraptene | 5 | 92.94 | 7.84 | 3 | 81.56 | 8.23 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 96 | Auraptene | 10 | 85.49 | 10.19 | 3 | 81.56 | 8.23 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 96 | Auraptene | 20 | 81.56 | 3.13 | 3 | 81.56 | 8.23 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 96 | Auraptene | 40 | 78.43 | 6.27 | 3 | 81.56 | 8.23 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 96 | Auraptene | 80 | 49.41 | 1.96 | 3 | 81.56 | 8.23 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 120 | Auraptene | 5 | 86.66 | 3.92 | 3 | 80.78 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 120 | Auraptene | 10 | 81.17 | 8.62 | 3 | 80.78 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 120 | Auraptene | 20 | 77.64 | 3.13 | 3 | 80.78 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 120 | Auraptene | 40 | 73.72 | 5.88 | 3 | 80.78 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 120 | Auraptene | 80 | 42.35 | 4.31 | 3 | 80.78 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 144 | Auraptene | 5 | 79.6 | 4.7 | 3 | 77.25 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 144 | Auraptene | 10 | 76.47 | 8.23 | 3 | 77.25 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 144 | Auraptene | 20 | 73.72 | 3.13 | 3 | 77.25 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 144 | Auraptene | 40 | 70.58 | 5.09 | 3 | 77.25 | 6.66 | 3 |
42 | Abolhassani et al. | 2,023 | Prostate | PC3 | 144 | Auraptene | 80 | 34.9 | 5.88 | 3 | 77.25 | 6.66 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 24 | Auraptene | 16.7 | 99.25 | 4.32 | 3 | 99.38 | 3.11 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 24 | Auraptene | 33.5 | 100.37 | 2.47 | 3 | 99.38 | 3.11 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 24 | Auraptene | 67 | 99.04 | 3.7 | 3 | 99.38 | 3.11 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 24 | Auraptene | 134 | 97.71 | 3.09 | 3 | 99.38 | 3.11 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 48 | Auraptene | 16.7 | 103.91 | 2.47 | 3 | 103.43 | 2.47 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 48 | Auraptene | 33.5 | 96.98 | 3.09 | 3 | 103.43 | 2.47 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 48 | Auraptene | 67 | 84.53 | 3.7 | 3 | 103.43 | 2.47 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 48 | Auraptene | 134 | 76.37 | 4.34 | 3 | 103.43 | 2.47 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 72 | Auraptene | 16.7 | 105.6 | 9.87 | 3 | 110.65 | 8 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 72 | Auraptene | 33.5 | 102.49 | 10.49 | 3 | 110.65 | 8 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 72 | Auraptene | 67 | 87.02 | 4.32 | 3 | 110.65 | 8 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 72 | Auraptene | 134 | 75.27 | 8.02 | 3 | 110.65 | 8 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 96 | Auraptene | 16.7 | 80.24 | 7.95 | 3 | 82.62 | 6.41 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 96 | Auraptene | 33.5 | 78.18 | 6.43 | 3 | 82.62 | 6.41 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 96 | Auraptene | 67 | 62.05 | 4.28 | 3 | 82.62 | 6.41 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 96 | Auraptene | 134 | 45.63 | 6.42 | 3 | 82.62 | 6.41 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 120 | Auraptene | 16.7 | 91.8 | 3.67 | 3 | 91.46 | 3.06 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 120 | Auraptene | 33.5 | 82.35 | 1.83 | 3 | 91.46 | 3.06 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 120 | Auraptene | 67 | 60.04 | 9.48 | 3 | 91.46 | 3.06 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 120 | Auraptene | 134 | 47.54 | 6.12 | 3 | 91.46 | 3.06 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 144 | Auraptene | 16.7 | 88.86 | 1.83 | 3 | 88.2 | 3.67 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 144 | Auraptene | 33.5 | 78.25 | 6.41 | 3 | 88.2 | 3.67 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 144 | Auraptene | 67 | 56.34 | 7.95 | 3 | 88.2 | 3.67 | 3 |
44 | Bagheri et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 144 | Auraptene | 134 | 40.24 | 1.83 | 3 | 88.2 | 3.67 | 3 |
46 | Afshari et al. | 2,019 | Glioblastoma | U87 | 8 | Auraptene | 167.6 | 70.16 | 2.76 | 3 | 100 | 1.65 | 3 |
46 | Afshari et al. | 2,019 | Glioblastoma | U87 | 8 | Auraptene | 335.2 | 51.93 | 3.31 | 3 | 100 | 1.65 | 3 |
46 | Afshari et al. | 2,019 | Glioblastoma | U87 | 24 | Auraptene | 167.6 | 57.91 | 3.34 | 3 | 100 | 2.09 | 3 |
46 | Afshari et al. | 2,019 | Glioblastoma | U87 | 24 | Auraptene | 335.2 | 42.5 | 2.91 | 3 | 100 | 2.09 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-29 | 72 | Auraptene | 2.5 | 90.94 | 4.53 | 3 | 99.62 | 12.45 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-29 | 72 | Auraptene | 5 | 86.41 | 4.53 | 3 | 99.62 | 12.45 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-29 | 72 | Auraptene | 10 | 75.09 | 7.55 | 3 | 99.62 | 12.45 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-29 | 72 | Auraptene | 20 | 55.09 | 16.6 | 3 | 99.62 | 12.45 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-29 | 72 | Auraptene | 40 | 28.3 | 2.26 | 3 | 99.62 | 12.45 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-116 | 72 | Auraptene | 2.5 | 86.41 | 9.43 | 3 | 100 | 9.05 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-116 | 72 | Auraptene | 5 | 84.9 | 19.62 | 3 | 100 | 9.05 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-116 | 72 | Auraptene | 10 | 70.18 | 19.63 | 3 | 100 | 9.05 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-116 | 72 | Auraptene | 20 | 56.6 | 3.77 | 3 | 100 | 9.05 | 3 |
47 | Epifano et al. | 2,013 | Colon | HT-116 | 72 | Auraptene | 40 | 45.66 | 17.35 | 3 | 100 | 9.05 | 3 |
48 | Moon et al. | 2,015 | Gastric | AGS | 48 | Auraptene | 12.5 | 92.84 | 13.58 | 3 | 100 | 2.91 | 3 |
48 | Moon et al. | 2,015 | Gastric | AGS | 48 | Auraptene | 25 | 80.73 | 9.91 | 3 | 100 | 2.91 | 3 |
48 | Moon et al. | 2,015 | Gastric | AGS | 48 | Auraptene | 50 | 48.44 | 6.23 | 3 | 100 | 2.91 | 3 |
AUR & UMB Anticancer Dataset
This dataset contains quantitative data on the anticancer effects of the natural coumarins Auraptene (AUR) and Umbelliprenin (UMB) across 27 studies. The data were collected from published literature reporting the impacts of AUR and UMB treatment on the viability of diverse human cancer cell lines.
Data Contents
The dataset is provided as a single .xlsx file containing three sheets: one for AUR, one for UMB, and one combined with the following columns:
author
: First author's last name from publicationyear
: Publication yearcancerType
: Cancer type examinedcellLine
: Specific cell line utilizedtime
: Treatment duration (in hours)coumarin
: Coumarin used (AUR or UMB)coumarinDose
: Dosage of coumarin (in μM)viability
: Mean viability (%) in treatment groupviabilitySD
: Standard deviation of treatment group viabilityviabilityN
: Number of repeats in treatment groupcontrol
: Mean viability (%) in control groupcontrolSD
: Standard deviation of control group viabilitycontrolN
: Number of repeats in control group
Usage Notes
The dataset can be loaded into Python, R, or statistical software packages for further analysis. The data structure allows examination of dose-response relationships and viability impacts of AUR and UMB across cancer types.
Standard deviations were estimated from within-study values when unavailable for specific data entries.
Data Access
The source data were obtained from published literature, as cited in this paper. The codes utilized in the paper are available at: https://github.com/moneuron/srep-meta-codes
- Downloads last month
- 0